Affymax, Inc. (NASDAQ:AFFY)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions.

Recs

0
Player Avatar punchy22 (< 20) Submitted: 6/28/2010 11:24:30 AM : Underperform Start Price: $6.75 AFFY Score: -88.55

This company is dead.

Featured Broker Partners


Advertisement